Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **topical combination drug** gel containing **heparinoid**, **escin**, and **diethylamine salicylate**. It is formulated for cutaneous application in the treatment of **sports-related and blunt impact injuries** (strains, sprains, contusions), as well as musculoskeletal pain and venous insufficiency. - **Heparinoids** possess anticoagulant and anti-inflammatory properties, improving local blood flow and preventing clot formation. - **Escin** (from horse chestnut seed extract) exerts anti-inflammatory, anti-edematous, and venotonic effects, mainly by stabilizing endothelial barriers and reducing microvascular permeability. - **Diethylamine salicylate** is a topical NSAID with analgesic, anti-inflammatory, and counterirritant actions, reducing musculoskeletal pain and inflammation. The gel demonstrates superior efficacy in reducing pain, tenderness, and swelling versus placebo and some single-ingredient comparators, with a rapid onset of symptom relief and a good safety profile[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparinoid + escin + diethylamine salicylate.